Minor aphthae associated with SARS‐CoV‐2 infection Dominguez‐Santas, Miguel; Diaz‐Guimaraens, Borja; Fernandez‐Nieto, Diego ...
International Journal of Dermatology,
August 2020, Volume:
59, Issue:
8
Journal Article
Background
Pliaglis® is a self‐occluding topical anesthetic containing a eutectic mixture of 7% lidocaine and 7% tetracaine, with proven efficacy and safety in several trials.
Aims
To evaluate the ...effectiveness and safety of Pliaglis® for different dermatological procedures in real‐life clinical practice.
Methods
This retrospective, multicenter study included 35 patients treated with Pliaglis® prior to five dermatological procedures (pulsed dyed laser, picosecond laser, non‐ablative fractional laser, radiofrequency microneedling, and photodynamic therapy). The primary endpoint was to assess the pain during the procedure with a visual analogue score (VAS) from 0 (no pain) to 10 (most severe pain). Secondary endpoints were the global effectiveness and tolerability (from 0 = very low to 10 = excellent), and the adverse events (AEs) after Pliaglis® removal, classified according to intensity (1–3).
Results
The median and mean pain VAS reported by patients was 2 (range 0–9) and 2.9 (±2.3), respectively. More than 65% of the patients had a VAS score ≤3. The effectiveness reported by investigators was “very good” (median 8 range 2–10, mean 7.5 ±1.9), which was strongly correlated with the pain VAS reported by patients (Spearman coefficient = ‐ 0.9; p < 0.001). Forty‐five percent of patients reported AEs and they were transient and mostly mild, with a mean intensity score of 1.5 (range 1–3). Tolerability of Pliaglis® was reported by investigators as “excellent” (median 10 range 1–10, mean 9 ±1.8).
Conclusions
Pliaglis® is an effective topical anesthetic for several dermatological procedures, with an excellent safety and tolerability profile.
low dose oral minoxidil (OM) is an increasingly used treatment for androgenetic alopecia and other types of hair loss. to analyze available data of patients treated with OM, focusing on safety and ...adverse effects. a search in PubMed and EMBASE was performed for studies reporting the treatment of alopecia with OM. Individual patient data available for pooled‐analysis were sex, dose of OM, presence of hypertrichosis and lower limb edema. 14 studies including 442 patients were analyzed. OM was used at doses between 0.25 and 5 mg, for eight different types of alopecia. Hypertrichosis was observed in 24% of patients. All doses had an increased odds ratio of hypertrichosis, compared to 0.25 to 0.5 mg (P < .001). Pedal edema was observed in 2% and was also associated with higher doses of OM (P = .009). Postural hypotension and heart rate alterations occurred only in 1.1% and 1.3% of the patients, respectively. Efficacy of OM could not be analyzed due to heterogeneous studies. However, four studies using OM for androgenetic alopecia reported a clinical response in 70% to 100% of the patients. Low dose OM is a safe and well‐tolerated treatment for hair loss, presenting a lower adverse effect rate than standard doses.
PDF
